PK and PD of a new beclomethasone dipropionate and formoterol CFC-free fixed combination

A. Piccinno, G. Poli, D. Acerbi, I. Burton, X. Druart (Parma, Italy; Wavre, Belgium)

Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Session: Recent advances in our understanding of the mechanisms of asthma treatment
Session type: Thematic Poster Session
Number: 2155
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Piccinno, G. Poli, D. Acerbi, I. Burton, X. Druart (Parma, Italy; Wavre, Belgium). PK and PD of a new beclomethasone dipropionate and formoterol CFC-free fixed combination. Eur Respir J 2007; 30: Suppl. 51, 2155

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 350s
Year: 2007

Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers
Source: Eur Respir J 2006; 28: Suppl. 50, 667s
Year: 2006

Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol
Source: Eur Respir J 2001; 18: Suppl. 33, 331s
Year: 2001

Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients
Source: Eur Respir J 2005; 26: Suppl. 49, 180s
Year: 2005

QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


Pharmacokinetic and pharmacodinamic effect of AeroChamber Plus spacer on the Extrafine beclometasone dipropionate plus formoterol combination (200/6 µg)
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010